Stockscreener 앱 받기
3.01
0.17%
0.04
전일 마감가:
$2.97
열려 있는:
$2.97
하루 거래량:
47,386
Relative Volume:
0.16
시가총액:
$18.93M
수익:
-
순이익/손실:
$-31.97M
주가수익비율:
-0.3644
EPS:
-8.2612
순현금흐름:
$-5.66M
1주 성능:
-1.49%
1개월 성능:
-21.71%
6개월 성능:
-39.41%
1년 성능:
-76.09%
1일 변동 폭
$2.9001
$3.145
1주일 범위
$2.695
$3.145
52주 변동 폭
$2.07
$15.96
Quantum Biopharma Ltd Stock (QNTM) Company Profile
Compare QNTM vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QNTM
Quantum Biopharma Ltd
|
2.9582 | 19.00M | 0 | -31.97M | -5.66M | -8.2612 |
VRTX
Vertex Pharmaceuticals Inc
|
490.25 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
695.00 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
871.97 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.19 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.76 | 37.17B | 4.29B | 577.22M | 641.34M | 4.2086 |
Quantum Biopharma Ltd 주식(QNTM)의 최신 뉴스
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Executive Outlines Lucid-MS Development Strategy and Commerc - Benzinga
Quantum BioPharma Ltd (QNTM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Quantum BioPharma Ltd (QNTM) Institutional Confidence - TradingKey
5 Stocks To BUY HEAVY Before June 2026 Pentagone Ovnis (6uU0VmOjAy) - Mshale
Quantum Biopharma Ltd. Subordinate Voting Shares Class B Revenue Breakdown – FWB:0K91 - TradingView
Quantum BioPharma Ltd (QNTM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
Quantum Biopharma Ltd. Subordinate Voting Shares Class B Revenue Breakdown – SWB:0K91 - TradingView
QNTM|Quantum BioPharma Ltd|Price:3.010|Chg%:+0.020 - TradingKey
Quantum BioPharma Ltd (QNTM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
QNTM|Quantum BioPharma Ltd|Price:2.935|Chg%:-0.055 - TradingKey
QNTM|Quantum BioPharma Ltd|Price:2.950|Chg%:-0.020 - TradingKey
QNTM|Quantum BioPharma Ltd|Price:3.035|Chg%:+0.065 - TradingKey
Quantum BioPharma Ltd (QNTM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Quantum Biopharma Ltd. (QNTM) Slides 2.1% as Support Levels Come into FocusSmall Cap Breakouts - dars.gov.et
Quantum BioPharma Ltd (QNTM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
QNTM: Quantum BioPharma Ltd Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Quantum BioPharma Ltd (QNTM) Fundamental & Financial Data - Stocktwits
Quantum BioPharma (QNTM) Developing Two-Pronged Attack on Brain Disorders Affecting Millions - Yahoo Finance
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Developing Two-Pronged Attack on Brain Disorders Affecting Millions - TradingView
Quantum BioPharma Plans to Settle Debt - marketscreener.com
Press Release: Quantum BioPharma Announces Intention to Settle Debt - Moomoo
Quantum BioPharma Announces Intention to Settle Debt - Sahm
Quantum BioPharma Ltd. Announces CAD$123,487 Debt Settlement Through Share Issuance - Quiver Quantitative
Quantum Biopharma Ltd. (QNTM) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Expands Clinical Development of Neuroprotective Therapy - USA Today
Quantum BioPharma (QNTM) Expands Clinical Development of Neuroprotective Therapy - NewMediaWire
Quantum Biopharma (NASDAQ: QNTM) (CSE: QNTM) Expands Clinical Development Of Neuroprotective Therapy - Menafn
Quantum BioPharma Advances Multiple Sclerosis Therapy LUCID-MS into Phase 2 Trials - citybuzz -
Why Quantum BioPharma (QNTM) Is 'One to Watch' - NewMediaWire
Why Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Is ‘One to Watch’ - Benzinga
Why Quantum Biopharma (NASDAQ: QNTM) (CSE: QNTM) Is 'One To Watch' - Menafn
Quantum BioPharma Advances Diversified Pipeline Targeting Neurodegenerative and Metabolic Disorders - citybuzz -
Quantum Biopharma Ltd. Q4 2025 Earnings: Widening Loss Amid Pre-Revenue Drug DevelopmentEarnings Volatility Report - DonanımHaber
Quantum Biopharma Ltd. (QNTM) Q4 2025 Earnings: Biotech Firm Reports Wider-Than-Expected Loss as Stock SlipsLow Estimate Range - dars.gov.et
AdvisorShares Trust holds 203,564 Class B shares in Quantum Biopharma (QNTM) - Stock Titan
Quantum BioPharma Provides Corporate Update - BNN Bloomberg
QNTM Should I Buy - Intellectia AI
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast - The Globe and Mail
Quantum BioPharma (QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast - Yahoo Finance
QNTM Q4 2025 Earnings: Biotech Reports Loss with No Revenue, Stock DeclinesEarnings Surprise Score - dars.gov.et
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study - The Globe and Mail
Quantum BioPharma (QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study - Yahoo Finance
Quantinuum (QNTM) Receives Strong Ratings, Shares Rise 5% in Pre-Market - GuruFocus
Quantum Biopharma Q4 2025 Earnings: Reports net loss of $0.71 per share as clinical‑stage biotech continues operationsFinancial Summary - dars.gov.et
Quantum Biopharma Ltd. Subordinate Voting Shares Class B Actuals & Estimates (BOATS:QNTM) - TradingView
QNTM Forecast — Price Target — Prediction for 2027 - TradingView
Quantum BioPharma Reaches Midpoint in MS Imaging Study, Early Results Show Promise - citybuzz -
Quantum BioPharma's Lucid-MS Targets Underlying Cause of Multiple Sclerosis in Growing $38.6B Market - citybuzz -
NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis - The Manila Times
NetworkNewsAudio Announces Audio Press Release (APR) the - GlobeNewswire
Quantum Biopharma Ltd (QNTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.96%
2.82%
자본화:
|
볼륨(24시간):